We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Privacy Terms and Cookie Policy
Balanced Reporting. Trusted Insights.
Tuesday, April 15, 2025
Gaps in the Food and Drug Administration’s authority and a lack of risk management planning slowed the federal government and industry’s ability to bounce back from the 2022 infant formula shortage, according to a recent report by the National Academies of Sciences Engineering and Medicine.
The Food and Drug Administration said it's taking action to address its handling of potential infant formular contamination, responding to a report from the Department of Health and Human Services’ inspector general that found FDA’s response to the 2022 crisis was woefully deficient.
Infant formula supplies are at risk because of the domination of state markets that formula makers have due to the way the Women, Infants and Children nutrition assistance program operates, according to a Federal Trade Commission report.
The lack of strong, defined leadership of the Food and Drug Administration’s human foods program has hindered the agency’s mission, says a report that is expected to shape FDA reform efforts.
The Food and Drug Administration is considering setting up a dedicated cadre of investigators for infant formula production as part of a strategy to prevent contamination of the product.
The milk industry is questioning the Food and Drug Administration's continued approval of infant formula imports from foreign manufacturers, even as the crisis begins to ease.
Online shopping and supply chain resiliency are two of the hallmark policies the Department of Agriculture plans to take to address infant formula access through the Supplemental Nutrition Program for Women, Infants, and Children.
